Grigoryan Gevorg 4

What Happened Gevorg Grigoryan, Chief Technology Officer of Generate Biomedicines (GENB), was granted two derivative awards on February 26, 2026 totaling 491,976 shares (295,608 and 196,368). Each grant shows an acquisition price of $0.00 on the Form 4, indicating these are compensation awards/options rather than an open-market purchase or sale. Vesting is time-based and contingent on continued service.

Key Details

• Transaction date: 2026-02-26; Filing date (Form 4): 2026-03-02 (filed timely within two business days).
• Grants: 295,608 shares @ $0.00 and 196,368 shares @ $0.00; total 491,976 shares awarded.
• Vesting (footnotes):
  • F1: 295,608 underlying shares vest in two equal installments on Feb 19, 2029 and Feb 19, 2030, subject to continued service.
  • F2: 196,368 underlying shares vest in 48 equal monthly installments beginning after Feb 19, 2026, subject to continued service.
• Ownership after transaction: not specified in the provided filing excerpt.
• Transaction type code: A = Grant/Award (derivative); not an exercise (no immediate share sale or cashless exercise reported).

Context These awards are standard equity compensation intended to align executive incentives with long-term company performance. Because no cash was paid and the shares vest over multiple years, this is a compensation grant rather than an immediate market investment; such grants are routine and do not by themselves indicate a near-term trading intention.